Allogene Therapeutics, Inc. ALLO
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of "off-the-shelf" T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.0K | $95.0K | $156.0K | $114.1M | $0 | $0 | — | — |
| R&D | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | $151.9M | — |
| SG&A | $56.8M | $65.2M | $71.7M | $79.3M | $74.1M | $65.3M | $57.5M | $41.0M | — |
| Total operating expenses | $209.3M | $273.2M | $327.8M | $335.7M | $294.3M | $258.2M | $202.0M | $192.8M | — |
| Operating income | -$209.3M | -$273.2M | -$327.7M | -$335.5M | -$180.2M | -$258.2M | -$202.0M | -$192.8M | — |
| Interest expense | $1.1M | $181.0K | $0 | — | — | $0 | $0 | $3.4M | — |
| Pre-tax income | -$190.9M | -$257.1M | -$327.3M | -$340.4M | -$257.0M | -$250.2M | -$184.9M | -$211.6M | — |
| Income tax | $0 | $443.0K | $0 | $0 | $0 | $0 | $331.0K | $117.0K | — |
| Net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M | -$316.4M | -$184.6M | -$211.5M | — |
| EPS, basic | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | — | — |
| EPS, diluted | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | -7.31 | — |
| Shares, diluted (wtd. avg.) | $220.6M | $194.8M | $156.9M | $143.1M | $135.8M | $120.4M | $101.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $51.7M | $75.2M | $93.4M | $72.2M | $173.3M | $192.8M | $179.4M | $93.7M | $0 |
| Short-term investments | $198.5M | $217.3M | $365.5M | $394.5M | $284.0M | $644.6M | $355.4M | $367.0M | — |
| Total current assets | $257.7M | $303.4M | $459.1M | $513.0M | $471.3M | $845.1M | $544.6M | $468.0M | — |
| Property, plant and equipment | $72.8M | $86.1M | $99.5M | $117.2M | $123.0M | $118.8M | $56.4M | $8.6M | — |
| Other intangibles | — | — | — | — | — | $0 | $151.0K | $754.0K | — |
| Total assets | $415.9M | $548.7M | $642.8M | $955.6M | $1.05B | $1.23B | $717.8M | $773.9M | — |
| Accounts payable | $4.3M | $5.4M | $5.9M | $9.7M | $10.3M | $10.4M | $9.2M | $12.3M | — |
| Total current liabilities | $32.5M | $35.5M | $37.1M | $44.2M | $47.9M | $94.3M | $33.1M | $29.5M | $2.0K |
| Total liabilities | $123.4M | $126.5M | $130.6M | $149.1M | $125.6M | $148.2M | $88.8M | $70.7M | $2.0K |
| Retained earnings | -$2.01B | -$1.82B | -$1.56B | -$1.05B | -$894.6M | -$712.5M | -$396.1M | -$211.5M | -$23.0K |
| Total equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M | $1.01B | $629.0M | $703.2M | -$2.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$149.2M | -$200.3M | -$237.7M | -$220.5M | -$184.8M | -$115.1M | -$137.3M | -$44.7M | — |
| Depreciation and amortisation | $12.4M | $13.6M | $14.2M | $14.3M | $10.5M | $7.4M | $4.6M | $1.0M | — |
| Stock-based compensation | $37.6M | $51.7M | $66.0M | $83.6M | $80.8M | $65.3M | $46.1M | $18.6M | — |
| Capital expenditure | $386.0K | $694.0K | $1.5M | $5.2M | $21.4M | $66.0M | $50.8M | $3.2M | — |
| Investing cash flow | $95.6M | $75.7M | $163.3M | $106.2M | $163.7M | -$505.1M | $164.1M | -$632.8M | — |
| Financing cash flow | $30.2M | $116.7M | $95.7M | $3.0M | $12.0M | $633.6M | $59.0M | $771.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028948.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |